Trial · NCT03464461
Dosing of Ketorolac in the Emergency Department
NCT03464461, Phase 4, Terminated, University of Missouri-Columbia; results first posted 2024-11-05
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Dosing of Ketorolac in the Emergency Department. Trials, record NCT03464461. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03464461
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dosing of Ketorolac in the Emergency Department
- NCT number
- NCT03464461
- Status
- Terminated
- Phases
- Phase 4
- Enrollment
- 289 participants, actual
- Lead sponsor
- University of Missouri-Columbia
- Conditions
- Acute Pain
- Interventions
- Ketorolac
- First posted
- 2018-03-14
- Last updated
- 2024-11-05
- Results first posted
- 2024-11-05
- Limitations and caveats
Study enrollment ended early, resulting in less than half of the number of participants needed according to the power analysis. Our study site was closed to enrollment during the recent pandemic, and there was major supply chain issues for saline and IV equipment. Ultimately the study was closed due to the extenuating circumstances.
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Difference of Pain Intensity Before and 30 Minute After Study Drug Administration in Participants With Any Pain Type | 30 minutes | The outcome measure is the average change in pain score. Change in pain score is calculated for each participant by subtracting the post-treatment pain score from the pretreatment pain score (i.e. pre-treatment pain score minus post-treatment pain score), then averaging them within each group. The pain score is collected using the visual analog scale, which is a 100mm line that participants make a mark on to indicate their pain intensity. The line is then measured from the left end of the line to where the mark was made. The minimum value is 0mm (left end of the line) being no pain and the maximum value is 100mm (right end of the line) being the worst pain possible. |
| Primary | Difference of Pain Intensity Before and 30 Minute After Study Drug Administration in Participants With Abdominal Pain | 30 minutes | The outcome measure is the average change in pain score. Change in pain score is calculated for each participant by subtracting the post-treatment pain score from the pretreatment pain score (i.e. pre-treatment pain score minus post-treatment pain score), then averaging them within each group. The pain score is collected using the visual analog scale, which is a 100mm line that participants make a mark on to indicate their pain intensity. The line is then measured from the left end of the line to where the mark was made. The minimum value is 0mm (left end of the line) being no pain and the maximum value is 100mm (right end of the line) being the worst pain possible. |
| Primary | Difference of Pain Intensity Before and 30 Minute After Study Drug Administration in Participants With Headache | 30 minutes | The outcome measure is the average change in pain score. Change in pain score is calculated for each participant by subtracting the post-treatment pain score from the pretreatment pain score (i.e. pre-treatment pain score minus post-treatment pain score), then averaging them within each group. The pain score is collected using the visual analog scale, which is a 100mm line that participants make a mark on to indicate their pain intensity. The line is then measured from the left end of the line to where the mark was made. The minimum value is 0mm (left end of the line) being no pain and the maximum value is 100mm (right end of the line) being the worst pain possible. |
| Primary | Difference of Pain Intensity Before and 30 Minute After Study Drug Administration in Participants With Trauma/Musculoskeletal Pain | 30 min | The outcome measure is the average change in pain score. Change in pain score is calculated for each participant by subtracting the post-treatment pain score from the pretreatment pain score (i.e. pre-treatment pain score minus post-treatment pain score), then averaging them within each group. The pain score is collected using the visual analog scale, which is a 100mm line that participants make a mark on to indicate their pain intensity. The line is then measured from the left end of the line to where the mark was made. The minimum value is 0mm (left end of the line) being no pain and the maximum value is 100mm (right end of the line) being the worst pain possible. |
| Primary | Difference of Pain Intensity Before and 30 Minute After Study Drug Administration in Participants With Viral Pain | 30 min | The outcome measure is the average change in pain score. Change in pain score is calculated for each participant by subtracting the post-treatment pain score from the pretreatment pain score (i.e. pre-treatment pain score minus post-treatment pain score), then averaging them within each group. The pain score is collected using the visual analog scale, which is a 100mm line that participants make a mark on to indicate their pain intensity. The line is then measured from the left end of the line to where the mark was made. The minimum value is 0mm (left end of the line) being no pain and the maximum value is 100mm (right end of the line) being the worst pain possible. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Difference of Pain Intensity Before and 30 Minute After Study Drug Administration in Participants With Any Pain Type | 30 minutes | Patients presenting to the Emergency Department with pain that falls in one of the for categories: abdominal, headache, trauma/musculoskeletal, viral | mm | MEAN |
| PRIMARY | Difference of Pain Intensity Before and 30 Minute After Study Drug Administration in Participants With Abdominal Pain | 30 minutes | Patients presenting to the Emergency Department with abdominal pain | mm | MEAN |
| PRIMARY | Difference of Pain Intensity Before and 30 Minute After Study Drug Administration in Participants With Headache | 30 minutes | Patients presenting to the Emergency Department with headache | mm | MEAN |
| PRIMARY | Difference of Pain Intensity Before and 30 Minute After Study Drug Administration in Participants With Trauma/Musculoskeletal Pain | 30 min | Patients presenting to the Emergency Department with trauma/musculoskeletal pain | mm | MEAN |
| PRIMARY | Difference of Pain Intensity Before and 30 Minute After Study Drug Administration in Participants With Viral Pain | 30 min | Patients presenting to the Emergency Department with viral pain | mm | MEAN |
Source ClinicalTrials.gov
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Difference of Pain Intensity Before and 30 Minute After Study Drug Administration in Participants With Any Pain Type | 0 mg | 15.1 | Standard Deviation 18.5 | mm | |
| Difference of Pain Intensity Before and 30 Minute After Study Drug Administration in Participants With Any Pain Type | 10 mg | 15.6 | Standard Deviation 19.4 | mm | |
| Difference of Pain Intensity Before and 30 Minute After Study Drug Administration in Participants With Any Pain Type | 30 mg | 16.7 | Standard Deviation 20.7 | mm | |
| Difference of Pain Intensity Before and 30 Minute After Study Drug Administration in Participants With Abdominal Pain | 0 mg | 12.4 | Standard Deviation 16.5 | mm | |
| Difference of Pain Intensity Before and 30 Minute After Study Drug Administration in Participants With Abdominal Pain | 10 mg | 19.4 | Standard Deviation 19.9 | mm | |
| Difference of Pain Intensity Before and 30 Minute After Study Drug Administration in Participants With Abdominal Pain | 30 mg | 22.1 | Standard Deviation 21.0 | mm | |
| Difference of Pain Intensity Before and 30 Minute After Study Drug Administration in Participants With Headache | 0 mg | 13.3 | Standard Deviation 14.8 | mm | |
| Difference of Pain Intensity Before and 30 Minute After Study Drug Administration in Participants With Headache | 10 mg | 10.8 | Standard Deviation 8.7 | mm | |
| Difference of Pain Intensity Before and 30 Minute After Study Drug Administration in Participants With Headache | 30 mg | 11.1 | Standard Deviation 18.4 | mm | |
| Difference of Pain Intensity Before and 30 Minute After Study Drug Administration in Participants With Trauma/Musculoskeletal Pain | 0 mg | 16.5 | Standard Deviation 21.0 | mm |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | 0 mg | 83 | |
| Overall Study | STARTED | 10 mg | 92 | |
| Overall Study | STARTED | 30 mg | 83 | |
| Overall Study | COMPLETED | 0 mg | 82 | |
| Overall Study | COMPLETED | 10 mg | 89 | |
| Overall Study | COMPLETED | 30 mg | 83 | |
| Overall Study | NOT COMPLETED | 0 mg | 1 | |
| Overall Study | NOT COMPLETED | 10 mg | 3 | |
| Overall Study | NOT COMPLETED | 30 mg | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | 0 mg | 0 | 82 |
| Total, all-cause mortality | 10 mg | 0 | 89 |
| Total, all-cause mortality | 30 mg | 0 | 83 |
| Total, other adverse events | 0 mg | 0 | 82 |
| Total, other adverse events | 10 mg | 0 | 89 |
| Total, other adverse events | 30 mg | 0 | 83 |
| Total, serious adverse events | 0 mg | 0 | 82 |
| Total, serious adverse events | 10 mg | 0 | 89 |
| Total, serious adverse events | 30 mg | 0 | 83 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03464461
GET https://conductscience.org/api/trials/v1/NCT03464461/registered